bit.bio at SLAS 2025

Visit us at booth 349

Attend our activities to learn how

opti-ox™ technology is empowering scientists to make pioneering discoveries

What if your in vitro human iPSC-derived cell models provided the consistency and scalability needed in drug discovery?

bit.bio's ioCells are deterministically programmed by opti-ox technology giving you unmatched consistency between every lot of cells. This built-in consistency enhances data reproducibility, eliminating variability and the need for repeated lot validations. With opti-ox , we can produce billions of consistently programmed cells that are ready to support the demands of your drug discovery workflows.

Join our exhibitor tutorial and review the data in our posters to discover how ioCells can advance drug discovery.

Users' posters

See how scientists are using ioCells in drug discovery — visit their posters 

 

Raising the bar in advanced high content analysis with future proof capabilities

Monday, January 27 | 12:00 AM - 1:00 PM | 1368-A | Cellular Technologies | Session A | Presented by Charles River Laboratories

Development and characterisation of a complex in vitro model for neuroinflammation/myelination and neurodegeneration using iPSC-derived cells

Tuesday, January 28 | 12:00 AM - 1:00 PM | 1366-C | Cellular Technologies | Session C | Presented by Charles River Laboratories

Exhibitor Tutorial

Challenges, solutions, and progress in applying human iPSC-derived cells to drug discovery

In drug discovery, researchers need reliable, ready-touse human cell models that deliver reproducible results at every stage of the workflow. Join four industry experts as they present data on bit.bio’s deterministically programmed human iPSC-derived ioCells used across key drug discovery stages. Through case studies and real-world applications, you will learn how these cells and the associated protocols support workflows in target identification, assay development, disease modelling, and toxicology.

Key learning points:

  • Discover quick and easy generation of gene knockouts and CRISPR screens for target ID and validation in human iPSC-derived neurons and microglia using CRISPR-Ready ioCells
  • Learn about assay development in neuroinflammation and demyelinating diseases using neuronal and glial co-cultures
  • Explore disease modelling in excitatory neurons with ALS-associated phenotypes using high-throughput MEA
  • See data for predicting drug-induced liver injury in toxicology studies with new human iPSC-derived liver models

Agenda

Date Tuesday, January 28 2025
Time 8:30 AM - 10:00 AM
Location Room 24B
Attendees Attendees will leave the session with knowledge of new solutions to generate human-relevant data in vitro to accelerate drug development.

Speakers

Tim smith round
Tim Smith, PhD Associate Director
Sales
bit.bio
Malika Bsibsi
Malika Bsibsi, PhD Research Leader

Neurosciences
Charles River Laboratories
Austin Axion
Austin Passaro, PhD Global Product Manager
MEA Systems

Axion BioSystems
Cicely Schramm Sartorius
Cicely Schramm, PhD Head of Biology
Cell Imaging
Sartorius
bit.bio_headshotsMay22_Pic0020_circle
Session Chair
Farah Patell Socha, PhD
VP Products
bit.bio

Discover how ioCells are being applied in real-world applications

bb-card-image-520-x-360-1-CaseStudy-SpeedingUpResearch

Quickly identify disease risk factors

Discover how Professor Srivastava, King's College London, generated publishable data in just 12 weeks with ioGlutamatergic Neurons.

bb-card-image-520-x-360-2-Video-ioGluts

Speed up discovery timelines

Learn how Charles River Laboratories are leveraging the benefits of ioGlutamatergic Neurons and how they are being incorporated into CNS drug discovery.

App note - inventia

Scalable 3D models for screening

Find out how Inventia Life Science generated functional 3D neuronal models in 96- and 384-well formats that closely resembled the human brain.

Browse ioCells portfolio

 
bitbio-cell_catalogue_header-with-tracker-Desktop-2500x1664

Book a meeting 

Complete the form and the right team member will be in touch with you